Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [
Algorithms
Fluorodeoxyglucose F18
Melanoma
Positron Emission Tomography / Computed Tomography
Skin neoplasms
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
12
02
2021
accepted:
04
03
2021
revised:
01
03
2021
pubmed:
27
3
2021
medline:
23
9
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
To compare block sequential regularized expectation maximization (BSREM) and ordered subset expectation maximization (OSEM) for the detection of in-transit metastasis (ITM) of malignant melanoma in digital [ We retrospectively analyzed a cohort of 100 [ BSREM reconstruction led to the detection of 287 ITM (39% more than OSEM). PET parameters of ITM were significantly different between BSREM and OSEM reconstructions (p < 0.001). SUVmax and TBR were higher (76.5% and 77.7%, respectively) and MTV lower (49.5%) on BSREM. ITM missed with OSEM had significantly lower SUVmax (mean 2.03 vs. 3.84) and TBR (mean 1.18 vs. 2.22) and higher MTV (mean 2.92 vs. 1.01) on OSEM compared to BSREM (all p < 0.001). BSREM detects significantly more ITM than OSEM, owing to higher SUVmax, higher TBR, and less blurring. BSREM is particularly helpful in small and less avid lesions, which are more often missed with OSEM. • In melanoma patients, [
Identifiants
pubmed: 33768288
doi: 10.1007/s00330-021-07852-7
pii: 10.1007/s00330-021-07852-7
pmc: PMC8452544
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8011-8020Informations de copyright
© 2021. The Author(s).
Références
Curr Oncol. 2020 Jun;27(3):e318-e325
pubmed: 32669939
Nucl Med Commun. 2017 Jan;38(1):57-66
pubmed: 27755394
Pediatr Radiol. 2020 Jun;50(7):966-972
pubmed: 32125447
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Eur J Surg Oncol. 2017 Mar;43(3):544-560
pubmed: 27923593
Ann Surg Oncol. 2015 Feb;22(2):358-60
pubmed: 25266867
Clin Nucl Med. 2018 May;43(5):370-371
pubmed: 29485444
Actas Dermosifiliogr. 2012 Apr;103(3):207-13
pubmed: 21899829
Sci Rep. 2021 Jan 26;11(1):2273
pubmed: 33500455
Br J Radiol. 2019 Apr;92(1096):20180792
pubmed: 30673302
EJNMMI Res. 2019 Jul 24;9(1):64
pubmed: 31342214
Ann Surg Oncol. 2015 Feb;22(2):475-81
pubmed: 25256128
Curr Radiopharm. 2020;13(1):14-23
pubmed: 31749439
J Nucl Med. 2019 Mar;60(3):335-341
pubmed: 30413661
Dermatol Clin. 2019 Oct;37(4):409-423
pubmed: 31466582
CA Cancer J Clin. 2016 Nov 12;66(6):460-480
pubmed: 27232110
J Immunother Cancer. 2020 May;8(1):
pubmed: 32376722
J Exp Clin Cancer Res. 2014 Nov 25;33:96
pubmed: 25420445
J Clin Oncol. 2002 Apr 15;20(8):2053-7
pubmed: 11956265
Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):110-118
pubmed: 29755844
PLoS One. 2013 Apr 29;8(4):e63137
pubmed: 23638183
J Oncol Pract. 2018 May;14(5):292-300
pubmed: 29746804
Br J Hosp Med (Lond). 2020 Sep 2;81(9):1
pubmed: 32990085
J Nucl Med. 2018 Jul;59(7):1152-1158
pubmed: 29449445
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Arch Surg. 1991 Dec;126(12):1461-8
pubmed: 1842174
Am J Nucl Med Mol Imaging. 2019 Apr 15;9(2):168-175
pubmed: 31139499
Crit Rev Oncol Hematol. 2020 Sep;153:103044
pubmed: 32673997
PLoS One. 2017 Jun 5;12(6):e0178936
pubmed: 28582472
J Nucl Med Technol. 2020 Dec;48(4):354-360
pubmed: 32887763
J Med Imaging Radiat Sci. 2019 Sep;50(3):460-469.e1
pubmed: 31204313
J Surg Oncol. 2020 Nov;122(6):1050-1056
pubmed: 32668038
EJNMMI Phys. 2018 Sep 26;5(1):27
pubmed: 30255439
Actas Dermosifiliogr. 2011 Dec;102(10):791-6
pubmed: 21658662
Ann Surg Oncol. 2018 Aug;25(8):2105-2110
pubmed: 29850954
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Nat Rev Dis Primers. 2015 Apr 23;1:15003
pubmed: 27188223